Research Article,

A Hospital-Based Study of EGFR and ALK Mutations in Patients with Lung Adenocarcinoma in Odisha

Prasant Kumar Parida¹, Sashibhusan Dash²

¹Assistant Professor, Department of Medical Oncology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, Odisha, India.
²Senior Research Fellow, Department of Oncopathology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, Odisha, India.

Corresponding Author email Address: drprasantdm@gmail.com

Abstract:

Background: Patients with advanced non-small cell lung cancer (NSCLC) have considerably benefited from the molecular identification of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations and subsequent targeted therapy against these biomarkers. Few studies have been undertaken in the Indian population on the analysis of both EGFR and ALK mutations in lung adenocarcinoma cases.

Aim and Objectives: The aim of this study was to determine the prevalence of EGFR and ALK mutations in lung adenocarcinoma patients, as well as to link mutational status with age, sex, and smoking history.

Materials and Methods: This single hospital-based retrospective study was conducted at the Department of Medical Oncology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, on histologically proven lung adenocarcinoma cases over a duration of two years from 01.08.2019 to 31.07.2021.

Results: Out of a total of 164 cases, males comprised 89 (54.26%) of the 164 lung adenocarcinoma cases, while females comprised 75 (45.73%). EGFR mutations were found in 42 (26.75%) of the patients. In 9 cases, the ALK gene rearrangement was also determined to be positive (5.66%). In terms of EGFR and ALK mutations, there was no statistically significant relationship between patient age and gender. (P-value < 0.05). In our research, we found a link between nonsmokers and EGFR and ALK mutations. (P-value < 0.05). The deletion of exon 19 (76.19%) was the most prevalent mutation, followed by the exon 21 L858R mutation (14.28%).

Conclusion: This study was found to have a significantly higher rate of EGFR and ALK mutation in the Indian population with adenocarcinoma of lung compared to Western populations. To get the maximum benefit from targeted therapies, all patients of adenocarcinoma of the lung should have mutational testing for EGFR and ALK as part of a broad molecular pannel.

Keywords: Anaplastic lymphoma kinase, epidermal growth factor receptor, lung adenocarcinoma

Introduction:

Lung cancer (LC), also known as bronchogenic carcinoma, is a kind of cancer that begins in the parenchyma or bronchi of the lungs. It is one of the most commonly diagnosed malignancies and the leading cause of cancer-related deaths worldwide, with an estimated 2 million new diagnoses and 176 million deaths per year. [1] In India, lung cancer accounts for 5.9% of all cancers and 8.1% of all cancer-related deaths. [2] The pathobiology of LC is exceedingly complex and poorly understood. Lung epithelial dysplasia is caused by repeated exposure to chemicals, mainly cigarette smoke. If the exposure continues, it leads to genetic mutations and affects protein synthesis. The cell cycle is interrupted as a result, which promotes carcinogenesis. [3] Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) are the two types of lung cancer, with NSCLC accounting for approximately 75–80 percent of all lung carcinomas. [4] Since the early 2000s, better knowledge of the molecular biology of NSCLC has resulted in significant improvements in the treatment of LC.
New molecular targets and driver mutations are being discovered. The EGFR tyrosine kinase domain undergoes active mutation, making it a therapeutic target. EGFR exons 18–21 of the EGFR gene's tyrosine kinase domain are associated with a high likelihood of responsiveness to EGFR tyrosine kinase inhibitors. A decade ago, a fraction of non-small cell lung cancer (NSCLC) patients had genetic rearrangements in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. These mutations are mutually exclusive. After the introduction of molecularly targeted medicines, the median survival duration increased from 12–14 months to 24–36 months. The prevalence of EGFR mutations varies among different populations, and these mutations are present at higher frequencies in women, in light or never-smokers, and in East Asian patients. The frequency of ALK rearrangements is approximately 5% in lung adenocarcinomas and is higher in light or never-smokers and in younger individuals. Identification of mutations in the epidermal growth factor receptor (EGFR) and (ALK) fusion genes has been recommended by the National Comprehensive Cancer Network (NCCN) in all lung adenocarcinoma patients as these markers are guiding the use of recently developed specific targeted therapies. Varied populations have different rates of EGFR and ALK mutations. Few studies have been undertaken in the Indian population on the analysis of both EGFR and ALK mutations in lung cancer cases. The objective of this study was to determine the prevalence of EGFR and ALK mutations in lung cancer patients, as well as to link mutational status with age, sex, and smoking history.

Materials and methods: This single hospital-based retrospective study was conducted at the Department of Medical Oncology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack for a duration of two years from 01.08.2019 to 31.07.2021. This study included all lung cancer patients diagnosed with adenocarcinoma in histology during the time period and who were then tested for both EGFR and ALK mutations. Inadequate materials and unsatisfactory samples were excluded from this study. The clinical data for the cases that were included was obtained from hospital records. Diagnostic procedures were performed according to the proposed 2011 adenocarcinoma classification by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society. Tissue biopsies from both the primary and metastatic locations were included in the study. PCR and gene sequencing were used to check for EGFR mutations. Microdissected cells from Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks were used for testing. The test was carried out on a tumor-rich area of FFPE tissue with > 40–50% cancer cells. Mutations in exons 18–21 of the EGFR gene were investigated. Fluorescence in Situ Hybridization (FISH) was used to detect the ALK gene rearrangement. The EGFR and ALK mutational analysis was outsourced and completed according to the previous protocol.

Statistics: All statistical calculations were done using the SPSS 17.0 statistical software. The chi-square test was used to compare the frequency of two groups. In all analyses, p-values were two-sided; values of less than 0.05 were considered statistically significant.

Table 1: Frequency of type of EGFR mutations in lung adenocarcinoma

| Type of exon | Mutation | Frequency (%) |
|-------------|----------|--------------|
| Exon 18     | G719 A,C | 2 (4.76%)    |
| Exon 19     | deE746-A750 | 32 (76.19%) |
| Exon 20     | S7681    | 2 (4.76%)    |
| Exon 21     | L858R    | 6 (14.28%)   |

Results: This study included 164 lung cancer patients who had their genes tested for EGFR mutations and ALK gene rearrangements.
Males made up 89 (54.26%) of the population, while females made up 75 (45.73%). At the time of diagnosis, the patients' ages ranged from 36 to 86. The percentage of smokers and former smokers in the male population was higher than in the female population. There were 70 (42.68%) nonsmokers, out of which 63 (84%) females and seven (7.86%) males. The majority of our patients (915.48%) had a lesion on the right side of their lungs.

40-two (26.75%) cases were positive for EGFR mutations out of 157 blocks analyzed. However, in 7 cases (4.26%), the result was inconclusive due to scanty or improperly processed tissue [Graph 1]. The frequency of EGFR mutational subtypes is shown in [Table 1].

ALK gene rearrangement was also found to be positive in 9 of the 159 cases. The positivity rate for ALK gene rearrangement was 5.66% after removing five (3.04%) cases that had unsatisfactory results on molecular analysis. Table 2 shows the EGFR mutation and ALK gene rearrangement status of lung cancer patients with clinical correlation.

Table 2: EGFR mutation and ALK gene rearrangement status of the lung adenocarcinoma patients with clinical correlation

| Characteristics | Total Cases N(%) | EGFR mutation status | P value | ALK gene rearrangement (n=159) | P value |
|-----------------|------------------|----------------------|---------|-----------------------------|---------|
|                 |                  | Mutated N(%)       | Wild type N(%) |              | Positive N(%) | Negative N(%) |
| Median age (range in years) | 58.3 (36-87) | 60 (36-82) | 59.87 (36-87) | .181 | 51.43 (36-71) | 56 (36-79) |
| Sex             |                  |                      |           |                            |         |
| Male            | 89 (54.26) | 27(64.28) | 58(50.43) | .66(66.66) | 81(54) | .458 |
| Female          | 75 (45.73) | 16(38) | 56(48.69) | 3(33.33) | 69(46) | .458 |
| Age             |                  |                      |           |                            |         |
| <50             | 53 (32.31) | 17(40.47) | 32(27.82) | .129 | 5(55.55) | 44(29.33) | .097 |
| >50             | 111(67.68) | 25(59.52) | 83(72.17) | 4(44.44) | 106(70.66) | .097 |
| Smoking status  |                  |                      |           |                            |         |
| Smoker/ Former smoker | 94(57.31) | 20(47.61) | 77(66.95) | .027* | 2(22.22) | 87(58) | .035* |
| Non smoker      | 70(42.68) | 22(52.38) | 38(33.43) | 7(77.77) | 63(42) | .035* |
| Total           | 164            | 42                  | 115      | 9                           | 150     |

* Result is showing significant at p value <0.05.

Table 3: The comparison between present study with previous study report about the frequency of EGFR mutation and ALK gene rearrangement of lung adenocarcinoma cases

| Characteristics | Rana et al. [11] | Dattatreya et al. [5] | Noronha et al. [21] | Kalal Iravarthy et al. [28] | Dutta et al. [20] | Chougle et al. [12] | Present study |
|-----------------|------------------|----------------------|---------------------|----------------------------|------------------|--------------------|----------------|
| Total cases     | 152              | 446                  | 267                 | 3351                       | 907              | 164                |               |
| Male            | 60.5%            | 68%                  | 25.86%              | 36.87%                     | 54.26%           | 45.73%             |                |
| Female          | 39.5%            | 32%                  | 74.14%              | 45.73%                     | 54.26%           |                    |                |
| Median age(year) | 57.5             | 60                   | 58.3                | 36.87%                     | 58.3             |                    |                |
| Range           | 25.86%           |                      |                     |                            |                  |                    |                |
| EGFR mutated    | 35.5%            | 24%                  | 20.59%              | 28.19%                     | 23%              | 26.75%             |                |
| Exon 18(G719A,C) | 4.2%             | 2.5%                 | 7%                  | 4.76%                      |                  |                    |                |
| Exon 19(%)      | 70.8%            | 73%                  | 74%                 | 56%                        | 72.99%           | 76.19%             |                |
| Exon 20(%)      | 4.2%             | 2.5%                 | 7%                  | 4.76%                      |                  |                    |                |
| ALK positive(%) | 7.6%             | 2.1%                 | 4.11%               | 2.53%                      | 5.66%            |                    |                |
Discussion:
Males outnumbered females in this study. Other research has shown similar results. Unlike other research, the cause of lung cancer in nonsmokers has remained unknown. According to the study reports, secondhand smoke, environmental exposures such as asbestos, arsenic, and radon, viruses such as the human papillomavirus, lung illnesses such as idiopathic pulmonary fibrosis, and indoor air pollutants such as fumes and smoke released from a coal burner are all attributable risk factors in nonsmokers. In our study, the right lung was found to be more commonly involved. This finding was consistent with previous studies done by Mohan et al. (52.3%). EGFR mutations occur at a rate of 10–15% in North Americans and Europeans, 19% in African-Americans, and 26–30% in various East Asian countries. Limited literature is available regarding the Indian population. The study involving the largest numbers of Indians has reported the incidence of EGFR mutations to be 26% in cases of lung adenocarcinoma, which is comparable to the rates in East Asian countries. A few studies from India reported a frequency of EGFR mutation ranging from 29% to 51.8% along with evidence of female dominance. In our analysis, the prevalence of EGFR mutations was found to be 26.75%, which is similar to the prevalence reported in other studies. However, some researchers have reported that the incidence is 35.5%. In contrast to the prior investigation, we found no statistically significant link between patient age and sex and the EGFR mutation. Other research has demonstrated the female gender’s dominance in cases of EGFR mutation. According to various research, EGFR mutations are more common in nonsmokers than in smokers. In our study, we discovered a significant association between nonsmokers and EGFR mutations, despite the fact that no such link was detected in another. Anti-EGFR therapy response has been linked to the existence of activating or driver mutations in exons 18–21 of the EGFR gene. In the literature, 45–54% of EGFR mutations are in-frame deletions in exon 19, 40% are missense mutations in L858R in exon 21, and 4–9% are EGFR mutations in exon 20. The prevalence of our EGFR mutation and ALK gene rearrangement in lung cancer cases is compared to previous research in Table 3. According to the study, exon 21 mutations were discovered to be more common in never-smoker females, while exon 19 mutations were found to be more common in non-smoker males, according to the study. Within India, the EGFR mutation frequency is distributed evenly across the country. Additionally, although exon 19 mutations are more common in nonsmokers, exon 21 mutations are more common among EGFR mutation-positive male smokers of Indian heritage. According to research, exon 18 EGFR mutations are found more commonly in younger people. Exon 18 mutations in lung cancer should not be disregarded in clinical practice. Although currently available in vitro diagnostic tools cannot detect all exon 18 mutations, these instances are best treated with afatinib or neratinib. According to a study, mutations in exon 21 were more common in females than in males, and one patient had a double mutation involving exons 20 and 21. In exon 20, one of the patients had an insertion-type deactivating mutation. There have been reports of uncommon EGFR mutations, and they are a heterogeneous group. As a result, it's crucial to learn more about each subgroup in order to figure out the best therapy alternatives. According to a study, when Indian patients with EGFR activating mutations were treated with EGFR-targeted therapies, their response rate, progression-free survival, and overall survival all increased significantly. The total incidence of ALK gene rearrangement in NSCLC is estimated to be between 2 and 7%. While conducting our research, we discovered a significant rate of ALK gene rearrangement involving exons 20 and 21. In contrast to a study, when Indian patients with EGFR activating mutations were treated with EGFR-targeted therapies, their response rate, progression-free survival, and overall survival all increased significantly. The high prevalence of ALK gene rearrangement in our patients highlights the need for molecular research to ensure that patients receive the most benefit from targeted medication. According to study data, the ALK gene rearrangement was shown to be positive in younger male patients, with a statistically significant link. However, no substantial difference was found in our research. Prior investigations were conducted into all of the cases that were evaluated for both EGFR and ALK mutations, and they were determined to be mutually
exclusive. (5, 11) This was also noticed in our research. According to the literature study, there have been 6–7 people worldwide who have had both mutations. Zhang et al. [30] described it in a paper published in 2010. They discovered a patient who had both EGFR and ALK mutations. This case was a Chinese woman who had histologically confirmed adenocarcinoma. Tanaka et al. [31] described a case of a 39-year-old man with acinar adenocarcinoma who had an EGFR mutation and an ALK fusion gene in 2012. In other research, two patients were discovered to have both mutations. The patients were 60 and 62-year-old men, respectively. Both displayed an acinar pattern, with histological grade I in one and histological grade II in the other. [4] When considering the use of targeted therapies such as EGFR inhibitors and/or ALK inhibitors, it’s critical to know the mutation status of both tumor-driving receptor genes in a single tumor. We also discovered equivocal results due to insufficient tissue or faulty processing, unlike earlier reports. [11] We also discovered equivocal results due to insufficient tissue or faulty processing, unlike earlier reports. [11] It is also recommended to test ALK and EGFR mutations simultaneously in light of the approval of targeted crizotinib therapy for ALK gene rearrangement and to maximise the use of limited tumor samples.

**Conclusion:**
This study found to have a significantly higher rate of EGFR and ALK mutation in Indian population with adenocarcinoma of lung compared to Western populations. To get the maximum benefit from targeted therapies, all patients of adenocarcinoma of lung should have mutational testing for EGFR and ALK as part of a broad molecular pannel.

Conflict of interest: Nil
Funding source: Nil

**References:**

[1] Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021; 398(10299):535-554.

[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jamal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424.

[3] Siddiqui F, Siddiqui AH. Lung Cancer. [Updated 2021 Sep 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482357/.

[4] Gupta P, Gowrishankar S, Swain M. Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns. Indian J Pathol Microbiol. 2019; 62:24-30.

[5] Dattatreya SP, Bansal R, Vamsy M, Vaniawala S, Nirni SS, Dayal M, Sharma R. Clinicopathological profile of lung cancer at a tertiary care center. Indian J Cancer. 2018; 55:273-275.

[6] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448:561-6.

[7] Brcic L, Jakopovic M, Misić M, Seiwerth F, Kern I, Smojver J, Quehenberger F, Samaržija M, Seiwerth S. Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. Diagn Pathol. 2016;11:90.

[8] Wang Y, Wang S, Xu S, Qu J, Liu B. Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. PLoS One. 2014; 9:e110617.

[9] NCCN Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer.2.2017.Available: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf Accessed 01.02.17.

[10] Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact
of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10:1243-1260.

[11] Rana V, Ranjan P, Jagani R, Rathi KR, Kumar D, Khera A. A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study. Med J Armed Forces India. 2018 ; 74:148-153.

[12] Choughule A, Noronha V, Joshi A, Desai S, Jambhekar N, Uttare S, Thavamanni A, Prabhash K, Dutt A. Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. Indian J Cancer. 2013; 50:107-11.

[13] Mohan A, Latifi AN, Guleria R. Increasing incidence of adenocarcinoma lung in India: Following the global trend? Indian J Cancer. 2016; 53:92-5.

[14] Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-500.

[15] Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 2005;16:1081-6.

[16] Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastrì AD, Soff GA, et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol. 2011; 6:28-31.

[17] Dong J, Hu Z, Wu C, Guo H, Zhou B, Lv J, et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet. 2012; 44:895-9.

[18] Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer. 2011; 73:316-9.

[19] Doval DC, Azam S, Batra U, Choudhury KD, Talwar V, Gupta SK, et al. Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study. J Carcinog. 2013; 12:12.

[20] Dutt S, Advani S.H, Dhabhar B.N, Dattatreya P.S, Patil S, Chatterjee S, et al. Experience of ALK mutation testing in 3351 Indian patients of NSCLC. Annals of Oncology. 2014;25 (Supplement 4): iv58–iv84.

[21] Noronha V, Prabhash K, Thavamani A, Choughule A, Purandare N, Joshi A, et al. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS One. 2013; 8:e61561.

[22] Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-57.

[23] Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004; 10:8195-203.

[24] Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res. 2015; 21:5305-13.

[25] Kwak E.L., Bang Y.J., Camidge D.R. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693–1703.

[26] Wong D.W., Leung E.L., So K.K., University of Hong Kong Lung Cancer Study Group The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild type EGFR and KRAS. Cancer. 2009; 115:1723–1733.

[27] Doval D.C, Prabhas K, Patil S. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther. 2015; 8:117–123.
[28] Kalal Iravathy G. Molecular diagnosis of lung cancers. Mol Enzymol Drug Targets 2015;1:1-8

[29] Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 2016; 8:e513.

[30] Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010; 9:188.

[31] Tanaka H, Hayashi A, Morimoto T, Taima K, Tanaka Y, Shimada M, et al. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer 2012; 12:558.